Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Zealand Pharma

249.40 DKK-0.68 %7.10, 17.10
Less than 1K followers

ZEAL

NASDAQ Copenhagen

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor views
Compare
-0.68 %
-18.34 %
-17.06 %
-16.31 %
-46.53 %
-51.12 %
-19.39 %
+36.06 %
+213.71 %

Zealand Pharma operates in biotechnology. Special focus is found in the development of drugs for the treatment of diabetes and various intestinal diseases. The company has a varied product portfolio with separate brands that are sold on a global level. The largest operations are in the Nordic market. Zealand Pharma was founded in 1997 and is headquartered in Søborg, Denmark.

Read more
Market cap
17.86B DKK
Turnover
80.95M DKK
Revenue
9.21B
EBIT %
75.52 %
P/E
2.72
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
12.11
2026

Interim report Q3'26

All
Research
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Regulatory press release07.10.2026, 19.13

Zealand Pharma announces positive Phase 2 ZUPREME-2 topline results for amylin analog petrelintide in people with overweight or obesity and type 2 diabetes

Zealand Pharma
Regulatory press release05.10.2026, 18.30

Zealand Pharma – Completion of share buy-back program and related transactions (week 40 and 41, 2026)

Zealand Pharma
HCA Morgenbørs 01/10 - Interview med Mohammad Lauritzen fra Fibo Invest og udsigt til en negativ åbning
Video01.10.2026, 09.36 by
Jacob Frehr, Michael Friis

HCA Morgenbørs 01/10 - Interview med Mohammad Lauritzen fra Fibo Invest og udsigt til en negativ åbning

Udsigt til en negativ åbning Europa trukket af Inflationstal l ikke lagde en dæmper på renter samt tech-rally på Micron. Herhjemme fokus på Gubra, Novo, Vestas. Gæst i studiet Mohammad Lauritzen fra Fibo Invest

PandoraTormHafniaBang & OlufsenNovo NordiskZealand PharmaGubraVestas Wind SystemsDSVCarlsberg

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release01.10.2026, 09.30

Zealand Pharma announces Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes

Zealand Pharma
Regulatory press release30.09.2026, 22.00

Total number of shares and voting rights in Zealand Pharma as of September 30, 2026

Zealand Pharma
Regulatory press release28.09.2026, 17.00

Zealand Pharma - Transactions related to share buy-back program (week 39, 2026)

Zealand Pharma
HCA Morgenbørs 22/09 – Interview med Thomas Black fra FBV og flad åbning i Europa
Video22.09.2026, 09.45 by
Michael Friis, Jacob Frehr

HCA Morgenbørs 22/09 – Interview med Thomas Black fra FBV og flad åbning i Europa

Europa ser ud til at åbne fladt op, og kan dermed ikke følge trop på de store stigninger i AI sektoren inspireret af en Muse. Herhjemme vil der blandt andet være fokus på Novo, Zealand, DSV Gæst i studiet her til morgen er Thomas Black fra FBV.

Novo NordiskDSVCadelerNordnetMetaØrstedTormZealand Pharma
Regulatory press release21.09.2026, 17.00

Zealand Pharma - Transactions related to share buy-back program (week 38, 2026)

Zealand Pharma
Regulatory press release14.09.2026, 17.00

Zealand Pharma - Transactions related to share buy-back program (week 37, 2026)

Zealand Pharma
Regulatory press release10.09.2026, 17.00

Zealand Pharma increases its share capital as a result of the exercise of employee warrants

Zealand Pharma
HCA Morgenbørs 08/09 - Napatech i fokus i interview med Anders Knudsen og stigende oliepriser
Video08.09.2026, 09.48 by
Jacob Frehr, Michael Friis

HCA Morgenbørs 08/09 - Napatech i fokus i interview med Anders Knudsen og stigende oliepriser

Udsigt til faldende aktiemarkeder fra morgenstunden i Europa på stigende oliepriser. Gæst i studiet her til morgen er Anders Knudsen, hvor vi sætter fokus på casen i Napatech.

NapatechZealand PharmaLundbeckNetcompany GroupGenmabISSNovo NordiskTorm
Regulatory press release07.09.2026, 17.00

Zealand Pharma - Transactions related to share buy-back program (week 36, 2026)

Zealand Pharma
Regulatory press release02.09.2026, 17.00

Correction: Zealand Pharma - Transactions related to share buy-back program (week 35, 2026)

Zealand Pharma
Regulatory press release31.08.2026, 17.00

Zealand Pharma - Transactions related to share buy-back program (week 35, 2026)

Zealand Pharma
Regulatory press release28.08.2026, 22.00

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

Zealand Pharma
HCA Morgenbørs 25/08 - ExpreS2ion CEO-interview og udsigt til en svag positiv åbning i Europa efter AI trade i Asien
Video25.08.2026, 09.41 by
Victor Skriver

HCA Morgenbørs 25/08 - ExpreS2ion CEO-interview og udsigt til en svag positiv åbning i Europa efter AI trade i Asien

Udsigt til en svag positiv åbning i Europa efter AI trade i Asien er vendt rundt til det positive i løbet af natten. Ingen større danske regnskaber i dag, fokus bl.a. på gårsdagens støre kursbevægelser. Gæst i studiet her til morgen er CEO Bent Frandsen fra Expres2ion.

ExpreS2ion BiotechColoplastCadelerHoveDanish Aerospace and Defence CompanyZealand Pharma
Regulatory press release24.08.2026, 17.05

Zealand Pharma – Notification of holding of treasury shares

Zealand Pharma
Regulatory press release24.08.2026, 17.00

Zealand Pharma - Transactions related to share buy-back program (week 34, 2026)

Zealand Pharma
Regulatory press release17.08.2026, 17.00

Zealand Pharma - Transactions related to share buy-back program (week 33, 2026)

Zealand Pharma
HCA Morgenbørs 13/08 - BioMar CEO-interview og fokus danske regnskab
Video13.08.2026, 09.21 by
Michael Friis, Victor Skriver

HCA Morgenbørs 13/08 - BioMar CEO-interview og fokus danske regnskab

Udsigt til positiv åbning i Europa, drevet af en let aftagende inflation i USA onsdag. Herhjemme er der fokus på de regnskabsaktuelle Mærsk, Zealand Pharma, Pandora og Netcompany. Gæst i studiet her til morgen er BioMar's CEO, Carlos Diaz.

BioMar GroupD/S NordenZealand PharmaPandoraØrstedA.P. Møller - Mærsk